Search

Your search keyword '"Gardin, Claude"' showing total 3 results
Start Over Author "Gardin, Claude" Journal leukemia & lymphoma
3 results on '"Gardin, Claude"'

1. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

Author

Astorgues-Xerri, Lucile, primary, Vázquez, Ramiro, additional, Odore, Elodie, additional, Rezai, Keyvan, additional, Kahatt, Carmen, additional, Mackenzie, Sarah, additional, Bekradda, Mohamed, additional, Coudé, Marie-Magdelaine, additional, Dombret, Herve, additional, Gardin, Claude, additional, Lokiec, Francois, additional, Raymond, Eric, additional, Noel, Kay, additional, Cvitkovic, Esteban, additional, Herait, Patrice, additional, Bertoni, Francesco, additional, and Riveiro, María E., additional

Published
2019
Full Text
View/download PDF

2. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Author

for the European ALMA + Investigators, Falantes, José, Itzykson, Raphael, Fenaux, Pierre, Pinto, Ricardo, Bargay, Joan, Burgstaller, Sonja, Martínez, María Pilar, Seegers, Valerie, Gardin, Claude, Cortesão, Emilia, Foncillas, María Ángeles, Montesinos, Pau, Sanz, Miguel Angel, Musto, Pellegrino, Pleyer, Lisa, Greil, Richard, Thépot, Sylvain, Almeida, António M., and Maurillo, Luca

Subjects
HEALTH of older people, MYELOID leukemia, AZACITIDINE, CANCER chemotherapy, HEMATOLOGIC malignancies
Abstract

Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8-16), 12.4 (95% CI, 9.9-14.8), and 8.1 months (95% CI, 7-9.1), respectively (p = .0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

3. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

Author

Cannas, Giovanna, primary, Pautas, Cécile, additional, Raffoux, Emmanuel, additional, Quesnel, Bruno, additional, Botton, Stéphane de, additional, Revel, Thierry de, additional, Reman, Oumedaly, additional, Gardin, Claude, additional, Elhamri, Mohamed, additional, Boissel, Nicolas, additional, Fenaux, Pierre, additional, Michallet, Mauricette, additional, Castaigne, Sylvie, additional, Dombret, Hervé, additional, and Thomas, Xavier, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results